CVS Health (NYSE:CVS - Get Free Report) had its price objective decreased by Royal Bank Of Canada from $113.00 to $108.00 in a research note issued on Monday, Benzinga reports. The firm currently has an "outperform" rating on the pharmacy operator's stock. Royal Bank Of Canada's price target suggests a potential upside of 19.87% from the company's current price.
Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of CVS Health from a "strong-buy" rating to a "buy" rating in a report on Monday, October 19th. TD Cowen reaffirmed a "buy" rating on shares of CVS Health in a report on Wednesday, November 4th. Wells Fargo & Company decreased their price target on shares of CVS Health from $123.00 to $112.00 and set an "overweight" rating on the stock in a research report on Thursday. Jefferies Financial Group reiterated a "buy" rating and issued a $103.00 price target on shares of CVS Health in a research report on Wednesday, November 4th. Finally, Raymond James Financial set a $103.00 price target on shares of CVS Health in a research note on Friday, November 6th. Twenty-three investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $107.33.
Read Our Latest Research Report on CVS Health
CVS Health Stock Performance
NYSE:CVS traded up $0.74 on Monday, hitting $90.09. The stock had a trading volume of 1,218,461 shares, compared to its average volume of 8,582,075. The stock has a market cap of $115.27 billion, a price-to-earnings ratio of 10.49, a price-to-earnings-growth ratio of 0.78 and a beta of 0.58. The company has a quick ratio of 0.66, a current ratio of 0.85 and a debt-to-equity ratio of 0.71. The business's 50-day simple moving average is $89.65 and its two-hundred day simple moving average is $89.09. CVS Health has a 52-week low of $69.51 and a 52-week high of $110.68.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.65 by $0.44. CVS Health had a return on equity of 13.65% and a net margin of 2.62%. The business had revenue of $108.40 billion during the quarter, compared to the consensus estimate of $104.72 billion. During the same period in the previous year, the company posted $1.60 EPS. The business's quarterly revenue was up 5.4% compared to the same quarter last year. As a group, research analysts predict that CVS Health will post 8.26 earnings per share for the current year.
Insider Buying and Selling at CVS Health
In related news, EVP Prem Shah acquired 23,855 shares of the stock in a transaction dated Friday, November 6th. The shares were purchased at an average cost of $83.89 per share, with a total value of $2,001,195.95. Following the transaction, the executive vice president directly owned 88,516 shares in the company, valued at approximately $7,425,607.24. This represents a 36.89% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.85% of the stock is currently owned by insiders.
Institutional Investors Weigh In On CVS Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers lifted its holdings in CVS Health by 4.8% during the third quarter. Cetera Investment Advisers now owns 501,082 shares of the pharmacy operator's stock valued at $42,938,000 after purchasing an additional 22,811 shares in the last quarter. Empirical Finance LLC increased its stake in shares of CVS Health by 1.9% in the third quarter. Empirical Finance LLC now owns 54,777 shares of the pharmacy operator's stock worth $4,694,000 after purchasing an additional 1,013 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of CVS Health in the third quarter worth $14,767,000. Flputnam Investment Management Co. increased its stake in shares of CVS Health by 136.7% in the third quarter. Flputnam Investment Management Co. now owns 79,944 shares of the pharmacy operator's stock worth $6,850,000 after purchasing an additional 46,166 shares in the last quarter. Finally, Acorns Advisers LLC raised its position in shares of CVS Health by 10.4% during the 3rd quarter. Acorns Advisers LLC now owns 3,353 shares of the pharmacy operator's stock valued at $287,000 after purchasing an additional 317 shares during the period. Institutional investors own 80.66% of the company's stock.
CVS Health Company Profile
(
Get Free Report)
CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.